TICKERNOMICS Sign up
Last Update: 2024-03-28 02:12:02
NEVRO CORP ( NVRO ) https://www.nevro.com
13.57USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-58.88%
NVRO
SPY
32.74%
-90.13%
NVRO
SPY
92.93%
-78.29%
NVRO
SPY
224.41%
NVRO
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
497.06
453.43
0.27
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-4.85
1.18
1.70
-9.31
0.00
-4.31
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-24.61
66.93
-25.51
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.7762
-21.23
-19.01
0.94
Other Earnings and Cash Flow Stats:
NEVRO CORP ( NVRO ) Net Income TTM ($MM) is 3.81
NEVRO CORP ( NVRO ) Operating Income TTM ($MM) is -104.16
NEVRO CORP ( NVRO ) Owners' Earnings Annual ($MM) is -69.97
NEVRO CORP ( NVRO ) Current Price to Owners' Earnings ratio is -7.05
NEVRO CORP ( NVRO ) EBITDA TTM ($MM) is -97.75
NEVRO CORP ( NVRO ) EBITDA Margin is -25.51%
Capital Allocation:
NEVRO CORP ( NVRO ) has paid 0.00 dividends per share and bought back -1.483031 million shares in the past 12 months
NEVRO CORP ( NVRO ) has reduced its debt by 182.855 million USD in the last 12 months
Capital Structure:
NEVRO CORP ( NVRO ) Interest-bearing Debt ($MM) as of last quarter is 211
NEVRO CORP ( NVRO ) Annual Working Capital Investments ($MM) are 56
NEVRO CORP ( NVRO ) Book Value ($MM) as of last quarter is 293
NEVRO CORP ( NVRO ) Debt/Capital as of last quarter is 72%
Other Balance Sheet Stats:
NEVRO CORP ( NVRO ) has 104 million in cash on hand as of last quarter
NEVRO CORP ( NVRO ) has 83 million of liabilities due within 12 months, and long term debt 211 as of last quarter
NEVRO CORP ( NVRO ) has 36 common shares outstanding as of last quarter
NEVRO CORP ( NVRO ) has 0 million USD of preferred stock value
Academic Scores:
NEVRO CORP ( NVRO ) Altman Z-Score is 0.24 as of last quarter
NEVRO CORP ( NVRO ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
NEVRO CORP ( NVRO ) largest shareholder is owning shares at 0.00 ($MM) value
Shawn Mccormick(an insider) Bought 7500 shares of NEVRO CORP ( NVRO ) for the amount of $171600.00 on 2023-06-07
2.81% of NEVRO CORP ( NVRO ) is held by insiders, and 102.93% is held by institutions
NEVRO CORP ( NVRO ) went public on 2014-11-06
Other NEVRO CORP ( NVRO ) financial metrics:
FCF:21.50
Unlevered Free Cash Flow:-116.09
EPS:-2.58
Operating Margin:-24.61
Gross Profit Margin:66.93
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-32.04
Beta:0.94
Buffet's Owners Earnings:-69.97
Price to Owner's Earnings:-7.05
About NEVRO CORP ( NVRO ) :
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation system for the treatment of chronic pain, as well as Senza II and Senza Omnia SCS systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company's Senza HFX iQ IPG system includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, it offers surpass surgical and percutaneous leads. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.